Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Toxoplasma gondii is a deadly intracellular parasite known to reside in every nucleated cell and known to cause severe complications in immunocompromised host. Standard drugs are cost effective and cause side effects, therefore, there is a necessity for a new drug molecule with immunomodulatory potential. Lactoferrin (Lf) is a natural milk protein, which has shown antimicrobial properties in its nanoformulation using alginate chitosan calcium phosphate bovine lactoferrin nanocapsules (AEC-CCo-CP-bLf-NCs). The present study was aimed to analyze and compare the effect of bovine Lf (bLf) in its native as well as nanoformulation (AEC-CCo-CP-bLf-NC) against coccidian parasite T. gondii. In vitro analysis has shown a significant increase in nitric oxide production and low parasitemia in in vitro cell culture model. In vivo BALB/c mice model have been used to develop human toxoplasmosis model. After treatment with NCs it has substantially increased the bioavailability of the protein and showed comparatively increased levels of reactive oxygen species, nitric oxide production, and Th1 cytokine which helped in parasite clearance. The mechanism of action of NCs has been clarified by immunoreactivity analysis, which showed accumulation of Lf in macrophages of various visceral organs, which is the site of parasite multiplication. Effect of NCs has significantly decreased (P<0.05) the parasite load in various organs and helped survival of mice till day 25 postinfection. Fe metabolism inside the mice has been found to be maintained even after administration of mono form of Lf, this indicates novelty of Lf protein. From the present study we concluded that nanoformulation did not reduce the therapeutic potential of Lf protein; however, nanoformulation has enhanced the stability of the protein and shown anti-toxoplasmal activity. Our study presents for the first time nanoformulation of Lf protein against Toxoplasma, which has advantages over the standard drug therapy without any side effects.

[1]  R. Kanwar,et al.  Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite–host interaction , 2015, Drug design, development and therapy.

[2]  Shufeng Zhou,et al.  Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions , 2015, Molecules.

[3]  R. Kanwar,et al.  Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. , 2015, Nanomedicine.

[4]  R. Kanwar,et al.  Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. , 2015, Nanomedicine.

[5]  Rasika M. Samarasinghe,et al.  The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. , 2014, Biomaterials.

[6]  Kuldeep Kumar,et al.  Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers. , 2014, Nanomedicine.

[7]  Y. Chawla,et al.  Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients , 2014, Molecular Biology Reports.

[8]  郑俊海,et al.  科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会 , 2014 .

[9]  R. Kanwar,et al.  Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. , 2012, Nanomedicine.

[10]  A. Brzostek,et al.  Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis , 2012, Bioengineered.

[11]  S. Parveen,et al.  Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[12]  N. León-Sicairos,et al.  Iron-saturated lactoferrin and pathogenic protozoa: could this protein be an iron source for their parasitic style of life? , 2012, Future microbiology.

[13]  S. Baratchi,et al.  Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity , 2011, Journal of Neuroimmunology.

[14]  Rongqin Huang,et al.  Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo , 2010, Brain Research Bulletin.

[15]  M. Garza,et al.  Microbicidal effect of the lactoferrin peptides Lactoferricin17–30, Lactoferrampin265–284, and Lactoferrin chimera on the parasite Entamoeba histolytica , 2010, BioMetals.

[16]  R. Das,et al.  Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[17]  J. Dziadek,et al.  Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. , 2009, Experimental parasitology.

[18]  M. Puri,et al.  Molecular and biotechnological advances in milk proteins in relation to human health. , 2009, Current protein & peptide science.

[19]  T. Ochoa,et al.  Effect of lactoferrin on enteric pathogens. , 2009, Biochimie.

[20]  G. Krissansen,et al.  ‘Iron‐saturated’ lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy , 2008, Immunology and cell biology.

[21]  J. Dziadek,et al.  Identification of Toxoplasma gondii proteins binding human lactoferrin: a new aspect of rhoptry proteins function. , 2007, Experimental parasitology.

[22]  G. Yap,et al.  Cytokine regulation of immunopathology in toxoplasmosis , 2007, Immunology and cell biology.

[23]  H. Baker,et al.  Molecular structure, binding properties and dynamics of lactoferrin. , 2005, Cellular and molecular life sciences : CMLS.

[24]  H. Nagasawa,et al.  The detection of bovine lactoferrin binding protein on Trypanosoma brucei. , 2004, The Journal of veterinary medical science.

[25]  T. Kanyshkova,et al.  Lactoferrin and Its biological functions , 2004, Biochemistry (Moscow).

[26]  E. Petersen,et al.  Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? , 2003, Expert review of anti-infective therapy.

[27]  R. Guerrant,et al.  Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. , 2003, The American journal of tropical medicine and hygiene.

[28]  K. Yamauchi,et al.  Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. , 2001, The Journal of veterinary medical science.

[29]  A. Bantjes,et al.  Preparation of apolactoferrin with a very low iron saturation. , 1995, Journal of dairy science.

[30]  F. Gillin,et al.  Giardicidal activity of lactoferrin and N-terminal peptides , 1995 .

[31]  F. Amano,et al.  Improved detection of nitric oxide radical (NO•) production in an activated macrophage culture with a radical scavenger, car☐y PTIO, and Griess reagent , 1995, FEBS letters.

[32]  J. Boothroyd,et al.  Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction , 1989, Journal of clinical microbiology.

[33]  D. Gatehouse,et al.  The use of a simple haematoxylin and eosin staining procedure to demonstrate micronuclei within rodent bone marrow. , 1986, Mutation research.

[34]  J. Wernicke,et al.  The Kinetics and Mechanism of Iron (III) Exchange between Chelates and Transferrin IV. THE REACTION OF TRANSFERRIN WITH IRON(III) NITRILOTRIACETATE , 1971 .

[35]  D. Young,et al.  Method for the automatic determination of serum iron , 1965, Journal of clinical pathology.